Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sucroferric oxyhydroxide - Vifor Pharma

Drug Profile

Sucroferric oxyhydroxide - Vifor Pharma

Alternative Names: Ferric oxyhydroxide; Ferrihydrite; Iron oxyhydroxide; P-TOL; PA-21; PA21-1; Phosphate binder - Vifor Pharma; suroferric oxyhydroxide; Velphoro

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vifor Pharma
  • Developer Fresenius Medical Care; Kissei Pharmaceutical; Vifor Fresenius Medical Care Renal Pharma; Vifor Pharma
  • Class Ferric compounds; Hyperphosphataemia therapies
  • Mechanism of Action Phosphate binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 17 Apr 2019 Vifor Fresenius Medical Care Renal Pharma terminates a phase III trial for Hyperphosphataemia (In neonates, In infants, In children, In adolescents) in USA, Lithuania, Germany, Poland, France, Romania and Russia due to the modification of study requirements by USFDA and EMA (PO, Tablet and Suspension) (NCT02688764)
  • 31 Aug 2018 Phase-III clinical trials in Hyperphosphataemia in China (PO) (NCT03644264)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top